CTLA4 and melanoma: For instance, a pioneering global prospective study analyzed the fecal samples of 39 patients with melanoma who underwent combined immunotherapy with anti-CTLA4 (ipilimumab) and anti-PD-1 (nivolumab) or anti-PD-1 treatment alone 263.